STOCK TITAN

[SCHEDULE 13G] Hinge Health, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Insight Entities disclosed beneficial ownership stakes in Hinge Health, Inc. (HNGE) via a joint Schedule 13G filing. The filing lists multiple reporting persons affiliated with Insight Partners, including IVP X funds, Insight Venture Associates entities and Insight Holdings Group, and gives the principal offices as c/o Insight Partners, 1114 Avenue of the Americas, New York.

The Reporting Persons report beneficial ownership of 11,029,604 shares of Class B Common Stock that are treated as issuable into Class A Common Stock on a one-for-one basis for percent calculations. On that basis, the Reporting Persons represent approximately 28.8% of the Class A Common Stock (calculated using 27,223,448 shares of Class A outstanding plus the Reporting Persons’ Class B shares). Individual cover-page totals include: IVP X (5,508,113 shares, 14.4%), IVP Cayman X (4,516,719 shares, 11.8%), IVP Delaware X (873,715 shares, 2.3%), IVP X Co-Investors (131,057 shares, 0.3%), and consolidated Insight entities holding the full 11,029,604 shares (28.8%). The filing is a joint submission and attaches a joint filing agreement as Exhibit 99.1.

Insight Entities ha dichiarato partecipazioni di proprietà beneficiaria in Hinge Health, Inc. (HNGE) tramite un deposito congiunto del modulo Schedule 13G. Il deposito elenca più soggetti segnalanti collegati a Insight Partners, tra cui i fondi IVP X, entità Insight Venture Associates e Insight Holdings Group, indicandone l'ufficio principale in c/o Insight Partners, 1114 Avenue of the Americas, New York.

I soggetti segnalanti dichiarano la proprietà beneficiaria di 11.029.604 azioni di Class B Common Stock, considerate convertibili in Class A Common Stock con rapporto uno a uno ai fini del calcolo percentuale. Su questa base, i soggetti segnalanti rappresentano circa 28,8% delle azioni di Class A Common Stock (calcolato usando 27.223.448 azioni di Class A in circolazione più le azioni Class B dei soggetti segnalanti). I totali nelle singole pagine di copertina includono: IVP X (5.508.113 azioni, 14,4%), IVP Cayman X (4.516.719 azioni, 11,8%), IVP Delaware X (873.715 azioni, 2,3%), IVP X Co-Investors (131.057 azioni, 0,3%) e le entità consolidate di Insight che detengono complessivamente le 11.029.604 azioni (28,8%). Il deposito è una dichiarazione congiunta e include l'accordo di deposito congiunto come Exhibit 99.1.

Insight Entities declaró participaciones de propiedad beneficiaria en Hinge Health, Inc. (HNGE) mediante una presentación conjunta del Schedule 13G. La presentación enumera a varias personas informantes afiliadas a Insight Partners, incluidos los fondos IVP X, entidades de Insight Venture Associates y Insight Holdings Group, indicando la oficina principal como c/o Insight Partners, 1114 Avenue of the Americas, New York.

Las personas informantes reportan la propiedad beneficiaria de 11.029.604 acciones de Class B Common Stock, que se consideran convertibles a Class A Common Stock en una proporción uno a uno para los cálculos porcentuales. Con base en esto, las personas informantes representan aproximadamente el 28,8% de las acciones de Class A Common Stock (calculado usando 27.223.448 acciones de Class A en circulación más las acciones Class B de las personas informantes). Los totales de las páginas de portada individuales incluyen: IVP X (5.508.113 acciones, 14,4%), IVP Cayman X (4.516.719 acciones, 11,8%), IVP Delaware X (873.715 acciones, 2,3%), IVP X Co-Investors (131.057 acciones, 0,3%) y las entidades consolidadas de Insight que poseen las 11.029.604 acciones (28,8%). La presentación es una declaración conjunta y adjunta un acuerdo de presentación conjunta como Exhibit 99.1.

Insight Entities는 공동 Schedule 13G 제출을 통해 Hinge Health, Inc.(HNGE)에 대한 실질적 소유 지분을 공시했습니다. 제출서에는 IVP X 펀드, Insight Venture Associates 관련 기관 및 Insight Holdings Group을 포함한 Insight Partners 소속의 여러 보고자가 기재되어 있으며, 주된 사무소는 c/o Insight Partners, 1114 Avenue of the Americas, New York로 명시되어 있습니다.

보고자들은 Class B 보통주 11,029,604주에 대한 실질적 소유를 보고했으며, 이는 비율 계산을 위해 1대1 비율로 Class A 보통주로 전환 가능한 것으로 취급됩니다. 이를 기준으로 보고자들은 Class A 보통주 가운데 약 28.8%를 보유한 것으로 나타납니다(계산은 유통 중인 Class A 27,223,448주에 보고자들의 Class B 주식을 더한 수를 사용). 개별 표지 페이지 합계는 다음과 같습니다: IVP X(5,508,113주, 14.4%), IVP Cayman X(4,516,719주, 11.8%), IVP Delaware X(873,715주, 2.3%), IVP X Co-Investors(131,057주, 0.3%) 및 통합된 Insight 계열사가 보유한 총 11,029,604주(28.8%). 이 제출은 공동 제출이며 Exhibit 99.1로 공동 제출 계약서를 첨부하고 있습니다.

Insight Entities a divulgué des participations bénéficiaires dans Hinge Health, Inc. (HNGE) via un dépôt conjoint du Schedule 13G. Le dépôt énumère plusieurs personnes déclarantes affiliées à Insight Partners, y compris les fonds IVP X, des entités Insight Venture Associates et Insight Holdings Group, et indique le siège principal comme c/o Insight Partners, 1114 Avenue of the Americas, New York.

Les personnes déclarantes indiquent détenir 11 029 604 actions de Class B Common Stock, considérées comme échangeables en Class A Common Stock selon un ratio un pour un pour les calculs de pourcentage. Sur cette base, elles représentent environ 28,8% des actions Class A Common Stock (calcul effectué en utilisant 27 223 448 actions Class A en circulation plus les actions Class B des déclarants). Les totaux figurant sur les pages de couverture individuelles comprennent : IVP X (5 508 113 actions, 14,4 %), IVP Cayman X (4 516 719 actions, 11,8 %), IVP Delaware X (873 715 actions, 2,3 %), IVP X Co-Investors (131 057 actions, 0,3 %) et les entités consolidées d'Insight détenant au total 11 029 604 actions (28,8 %). Le dépôt est une déclaration conjointe et joint un accord de dépôt conjoint en tant qu'Exhibit 99.1.

Insight Entities meldete wirtschaftliche Eigentumsanteile an Hinge Health, Inc. (HNGE) durch eine gemeinsame Schedule 13G-Einreichung. Die Einreichung listet mehrere meldende Personen im Zusammenhang mit Insight Partners auf, darunter IVP X-Fonds, Einheiten von Insight Venture Associates und Insight Holdings Group, und nennt die Hauptgeschäftsstelle als c/o Insight Partners, 1114 Avenue of the Americas, New York.

Die meldenden Personen geben den wirtschaftlichen Besitz von 11.029.604 Aktien der Class B Common Stock an, die für Prozentberechnungen als eins-zu-eins in Class A Common Stock umwandelbar gelten. Auf dieser Basis vertreten die meldenden Personen etwa 28,8% der Class A Common Stock (berechnet mit 27.223.448 ausstehenden Class A-Aktien zuzüglich der Class B-Aktien der meldenden Personen). Einzelne Deckblatt-Summen umfassen: IVP X (5.508.113 Aktien, 14,4%), IVP Cayman X (4.516.719 Aktien, 11,8%), IVP Delaware X (873.715 Aktien, 2,3%), IVP X Co-Investors (131.057 Aktien, 0,3%) und konsolidierte Insight-Einheiten, die insgesamt 11.029.604 Aktien (28,8%) halten. Die Einreichung ist eine gemeinsame Erklärung und fügt als Exhibit 99.1 eine Vereinbarung zur gemeinsamen Einreichung bei.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insight-affiliated funds disclosed a substantial convertible stake in Hinge Health totaling 11,029,604 Class B shares, representing 28.8% for class-calculation purposes.

The filing provides clear, quantifiable ownership percentages and shows that the stake is composed of Class B shares treated as convertible into Class A for percentage calculations. This concentration—11,029,604 shares versus 27,223,448 reported Class A outstanding—is material to capitalization metrics and could affect voting-power calculations if conversions occur. The report also separates holdings by specific Insight entities, aiding transparency for cap table analysis. No details are provided about plans, intent, or transactions beyond beneficial ownership and the joint-filing arrangement.

TL;DR: A coordinated joint filing discloses substantial beneficial ownership derived from Class B shares convertible one-for-one, a material governance disclosure.

The Schedule 13G identifies multiple affiliated reporting persons and a joint filing agreement, which clarifies that the Insight Entities submitted a single, consolidated disclosure though they disclaim group membership for other purposes. The treatment of Class B shares as convertible for the percent calculation is explicitly stated, which is important when assessing potential changes to voting power and control dynamics. The filing does not state any proposed actions or changes in intent, limiting governance conclusions to ownership structure only.

Insight Entities ha dichiarato partecipazioni di proprietà beneficiaria in Hinge Health, Inc. (HNGE) tramite un deposito congiunto del modulo Schedule 13G. Il deposito elenca più soggetti segnalanti collegati a Insight Partners, tra cui i fondi IVP X, entità Insight Venture Associates e Insight Holdings Group, indicandone l'ufficio principale in c/o Insight Partners, 1114 Avenue of the Americas, New York.

I soggetti segnalanti dichiarano la proprietà beneficiaria di 11.029.604 azioni di Class B Common Stock, considerate convertibili in Class A Common Stock con rapporto uno a uno ai fini del calcolo percentuale. Su questa base, i soggetti segnalanti rappresentano circa 28,8% delle azioni di Class A Common Stock (calcolato usando 27.223.448 azioni di Class A in circolazione più le azioni Class B dei soggetti segnalanti). I totali nelle singole pagine di copertina includono: IVP X (5.508.113 azioni, 14,4%), IVP Cayman X (4.516.719 azioni, 11,8%), IVP Delaware X (873.715 azioni, 2,3%), IVP X Co-Investors (131.057 azioni, 0,3%) e le entità consolidate di Insight che detengono complessivamente le 11.029.604 azioni (28,8%). Il deposito è una dichiarazione congiunta e include l'accordo di deposito congiunto come Exhibit 99.1.

Insight Entities declaró participaciones de propiedad beneficiaria en Hinge Health, Inc. (HNGE) mediante una presentación conjunta del Schedule 13G. La presentación enumera a varias personas informantes afiliadas a Insight Partners, incluidos los fondos IVP X, entidades de Insight Venture Associates y Insight Holdings Group, indicando la oficina principal como c/o Insight Partners, 1114 Avenue of the Americas, New York.

Las personas informantes reportan la propiedad beneficiaria de 11.029.604 acciones de Class B Common Stock, que se consideran convertibles a Class A Common Stock en una proporción uno a uno para los cálculos porcentuales. Con base en esto, las personas informantes representan aproximadamente el 28,8% de las acciones de Class A Common Stock (calculado usando 27.223.448 acciones de Class A en circulación más las acciones Class B de las personas informantes). Los totales de las páginas de portada individuales incluyen: IVP X (5.508.113 acciones, 14,4%), IVP Cayman X (4.516.719 acciones, 11,8%), IVP Delaware X (873.715 acciones, 2,3%), IVP X Co-Investors (131.057 acciones, 0,3%) y las entidades consolidadas de Insight que poseen las 11.029.604 acciones (28,8%). La presentación es una declaración conjunta y adjunta un acuerdo de presentación conjunta como Exhibit 99.1.

Insight Entities는 공동 Schedule 13G 제출을 통해 Hinge Health, Inc.(HNGE)에 대한 실질적 소유 지분을 공시했습니다. 제출서에는 IVP X 펀드, Insight Venture Associates 관련 기관 및 Insight Holdings Group을 포함한 Insight Partners 소속의 여러 보고자가 기재되어 있으며, 주된 사무소는 c/o Insight Partners, 1114 Avenue of the Americas, New York로 명시되어 있습니다.

보고자들은 Class B 보통주 11,029,604주에 대한 실질적 소유를 보고했으며, 이는 비율 계산을 위해 1대1 비율로 Class A 보통주로 전환 가능한 것으로 취급됩니다. 이를 기준으로 보고자들은 Class A 보통주 가운데 약 28.8%를 보유한 것으로 나타납니다(계산은 유통 중인 Class A 27,223,448주에 보고자들의 Class B 주식을 더한 수를 사용). 개별 표지 페이지 합계는 다음과 같습니다: IVP X(5,508,113주, 14.4%), IVP Cayman X(4,516,719주, 11.8%), IVP Delaware X(873,715주, 2.3%), IVP X Co-Investors(131,057주, 0.3%) 및 통합된 Insight 계열사가 보유한 총 11,029,604주(28.8%). 이 제출은 공동 제출이며 Exhibit 99.1로 공동 제출 계약서를 첨부하고 있습니다.

Insight Entities a divulgué des participations bénéficiaires dans Hinge Health, Inc. (HNGE) via un dépôt conjoint du Schedule 13G. Le dépôt énumère plusieurs personnes déclarantes affiliées à Insight Partners, y compris les fonds IVP X, des entités Insight Venture Associates et Insight Holdings Group, et indique le siège principal comme c/o Insight Partners, 1114 Avenue of the Americas, New York.

Les personnes déclarantes indiquent détenir 11 029 604 actions de Class B Common Stock, considérées comme échangeables en Class A Common Stock selon un ratio un pour un pour les calculs de pourcentage. Sur cette base, elles représentent environ 28,8% des actions Class A Common Stock (calcul effectué en utilisant 27 223 448 actions Class A en circulation plus les actions Class B des déclarants). Les totaux figurant sur les pages de couverture individuelles comprennent : IVP X (5 508 113 actions, 14,4 %), IVP Cayman X (4 516 719 actions, 11,8 %), IVP Delaware X (873 715 actions, 2,3 %), IVP X Co-Investors (131 057 actions, 0,3 %) et les entités consolidées d'Insight détenant au total 11 029 604 actions (28,8 %). Le dépôt est une déclaration conjointe et joint un accord de dépôt conjoint en tant qu'Exhibit 99.1.

Insight Entities meldete wirtschaftliche Eigentumsanteile an Hinge Health, Inc. (HNGE) durch eine gemeinsame Schedule 13G-Einreichung. Die Einreichung listet mehrere meldende Personen im Zusammenhang mit Insight Partners auf, darunter IVP X-Fonds, Einheiten von Insight Venture Associates und Insight Holdings Group, und nennt die Hauptgeschäftsstelle als c/o Insight Partners, 1114 Avenue of the Americas, New York.

Die meldenden Personen geben den wirtschaftlichen Besitz von 11.029.604 Aktien der Class B Common Stock an, die für Prozentberechnungen als eins-zu-eins in Class A Common Stock umwandelbar gelten. Auf dieser Basis vertreten die meldenden Personen etwa 28,8% der Class A Common Stock (berechnet mit 27.223.448 ausstehenden Class A-Aktien zuzüglich der Class B-Aktien der meldenden Personen). Einzelne Deckblatt-Summen umfassen: IVP X (5.508.113 Aktien, 14,4%), IVP Cayman X (4.516.719 Aktien, 11,8%), IVP Delaware X (873.715 Aktien, 2,3%), IVP X Co-Investors (131.057 Aktien, 0,3%) und konsolidierte Insight-Einheiten, die insgesamt 11.029.604 Aktien (28,8%) halten. Die Einreichung ist eine gemeinsame Erklärung und fügt als Exhibit 99.1 eine Vereinbarung zur gemeinsamen Einreichung bei.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 5,508,113 shares of Class A Common Stock issuable upon the exchange of such 5,508,113 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 4,516,719 shares of Class A Common Stock issuable upon the exchange of such 4,516,719 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 873,715 shares of Class A Common Stock issuable upon the exchange of such 873,715 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 131,057 shares of Class A Common Stock issuable upon the exchange of such 131,057 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 11,029,604 shares of Class A Common Stock issuable upon the exchange of such 11,029,604 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 11,029,604 shares of Class A Common Stock issuable upon the exchange of such 11,029,604 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9 include 11,029,604 shares of Class A Common Stock issuable upon the exchange of such 11,029,604 shares of Class B Common Stock for Class A Common Stock on a one-for-one basis. See Item 4(b) for further information regarding Row 11. Percentage ownership is based on 38,253,052 shares of Class A Common Stock, which is the sum of (x) 27,223,448 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and (y) 11,029,604 shares of Class A Common Stock issuable upon the exchange of all shares of Class B Common Stock held by the Reporting Persons, but assuming no exchange of any other shares of Class B Common Stock. `


SCHEDULE 13G



Insight Venture Partners X, LP
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Partners X, LP
Date:08/14/2025
Insight Venture Partners (Cayman) X, LP
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Partners (Cayman) X, LP
Date:08/14/2025
Insight Venture Partners (Delaware) X, LP
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Partners (Delaware) X, LP
Date:08/14/2025
Insight Venture Partners X (Co-Investors), LP
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Partners X (Co-Investors), LP
Date:08/14/2025
Insight Venture Associates X, L.P.
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Associates X, L.P.
Date:08/14/2025
Insight Venture Associates X, Ltd.
Signature:/s/ Andrew Prodromos
Name/Title:Insight Venture Associates X, Ltd.
Date:08/14/2025
Insight Holdings Group, LLC
Signature:/s/ Andrew Prodromos
Name/Title:Insight Holdings Group, LLC
Date:08/14/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement, as required by Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended

Hinge Health, Inc.

NYSE:HNGE

HNGE Rankings

HNGE Latest News

HNGE Latest SEC Filings

HNGE Stock Data

4.55B
13.67M
86.7%
19.15%
1.84%
Health Information Services
Services-computer Processing & Data Preparation
Link
United States
SAN FRANCISCO